🇺🇸 FDA
Patent

US 12091426

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

granted A61PA61P35/00A61P37/02

Quick answer

US patent 12091426 (Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof) held by NURIX THERAPEUTICS, INC. expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
NURIX THERAPEUTICS, INC.
Grant date
Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P35/00, A61P37/02